Last reviewed · How we verify
Generic Zoledronic Acid
Zoledronic acid inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
Zoledronic acid inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Used for Metastatic bone disease in cancer patients, Multiple myeloma with bone involvement, Osteoporosis.
At a glance
| Generic name | Generic Zoledronic Acid |
|---|---|
| Also known as | Yigu |
| Sponsor | Cttq |
| Drug class | Bisphosphonate |
| Target | Farnesyl pyrophosphate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology, Bone Metabolism |
| Phase | FDA-approved |
Mechanism of action
As a bisphosphonate, zoledronic acid binds to hydroxyapatite in bone and is taken up by osteoclasts during bone resorption. It inhibits farnesyl pyrophosphate synthase, disrupting the prenylation of small GTPases required for osteoclast function and survival, leading to decreased bone turnover and increased bone mineral density.
Approved indications
- Metastatic bone disease in cancer patients
- Multiple myeloma with bone involvement
- Osteoporosis
- Paget's disease of bone
- Hypercalcemia of malignancy
Common side effects
- Osteonecrosis of the jaw
- Atypical femoral fractures
- Renal impairment
- Fever
- Myalgia/arthralgia
- Nausea
Key clinical trials
- Denosumab Safety Assessment in Multiple Observational Databases
- Generic Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Generic Zoledronic Acid CI brief — competitive landscape report
- Generic Zoledronic Acid updates RSS · CI watch RSS
- Cttq portfolio CI